elimusertib
Small moleculeexperimental
Clinical trial activity
10 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 26, 2017 (NCT03188965)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Bile Duct Neoplasms · Phase 1
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Ovarian Epithelial · Phase 1
- Carcinoma, Squamous Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Colorectal Neoplasms · Phase 1
- Digestive System Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Hamartoma · Phase 1
- Head and Neck Neoplasms · Phase 1
- Hypopharyngeal Neoplasms · Phase 1
- Laryngeal Neoplasms · Phase 1
- Lung Neoplasms · Phase 1
- Lymphoma · Phase 1/Phase 2
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Mesothelioma · Phase 1
- Mouth Neoplasms · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1/Phase 2
- Neuroendocrine Tumors · Phase 1
- Oropharyngeal Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Penile Neoplasms · Phase 1
- Rhabdomyosarcoma · Phase 1/Phase 2
- Salivary Gland Neoplasms · Phase 1
- Sarcoma, Ewing · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Stomach Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- ATR/ATRIPINHIBITOR
ATR/ATRIP inhibitor
- Serine-protein kinase ATRINHIBITOR
Serine-protein kinase ATR inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1- Mol. weight
- 375.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4647810 ↗
Also known as
- bay1895344
- bay1895344
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05071209 | Phase 1/Phase 2 (Phase 2) | Dec 3, 2021 | National Cancer Institute (NCI) |
| NCT05010096 | Phase 1 | Dec 2, 2021 | University of Texas at Houston |
| NCT04514497 | Phase 1 | Feb 11, 2021 | National Cancer Institute (NCI), Yale University |
| NCT04535401 | Phase 1 | Dec 31, 2020 | National Cancer Institute (NCI), University of Pittsburgh |
| NCT04491942 | Phase 1 | Dec 31, 2020 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT04576091 | Phase 1 | Dec 31, 2020 | National Cancer Institute (NCI), University of Pittsburgh |
| NCT04616534 | Phase 1 | Dec 31, 2020 | Harvard University, National Cancer Institute (NCI) |
| NCT04267939 | Phase 1 | Feb 19, 2020 | Bayer |
| NCT04095273 | Phase 1 | Sep 27, 2019 | Bayer |
| NCT03188965 | Phase 1 | Jun 26, 2017 | Bayer |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 6 | 6 | 2 | 2020 |
| Bayer | For profit | 3 | 3 | 1 | 2017 |
| University of Pittsburgh | Academic/Hospital | 2 | 0 | 1 | 2020 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2021 |
7 organizations
Page 1 / 1